Obviously there was no "subset analysis" for the basic overall survival analysis. That was statistically significant whether you examine 9901 or 9901 and 9902A combined. David's argument in rebuttal to Scherr's argument that the placebo itself mightt have a negative effect is a subset analysis, but given the design of 9902B -- the subject of an SPA -- I suspect we will never run a trial of Provenge v. inert placebo. If the FDA approves, obviously that won't happen, and if they require waiting till 9902B results are in.
Market Data 
Markets 
AI
